Clinical Trials Logo

Clinical Trial Summary

In the field of cancer treatment, it is generally accepted that the enhancement of oxygen delivery to tumors can augment the effect of anti-cancer therapies. In the case of chemotherapy, this enhancement might lead to a larger amount of a given dose of treatment reaching the tumor and having an effect.


Clinical Trial Description

While the benefits of exercise on overall health are widely documented, little is known about how exercise affects the progression or treatment of malignant neoplasms. Tumors have a complex vascular network which is likely affected by the global changes in hemodynamics and perfusion that occur during moderate exercise. Increased tumor oxygenation is clinically relevant as it may counteract the hypoxic tumor environment which is known to contribute to resistance to chemo- and radiation therapies, angiogenesis, invasiveness and metastasis, genomic instability, and resistance to cell death. The researcher can use noninvasive optical imaging technology called diffuse optical spectroscopy to safely and non-invasively quantify the dynamics of blood flow and metabolism in tumors and normal tissue of subjects undergoing supervised cycling exercise. The researcher can determine that exercise will measurably increase tumor oxygenation, and that this effect will be proportional to the intensity and/or duration of the exercise performed. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02340468
Study type Observational
Source University of California, Irvine
Contact
Status Withdrawn
Phase
Start date April 2015
Completion date January 2018

See also
  Status Clinical Trial Phase
Recruiting NCT05544123 - The Treatment Situation of Chinese County Population With Breast Cancer
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Withdrawn NCT05191004 - Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC Phase 1/Phase 2
Active, not recruiting NCT01247480 - Analysis of Prognostic and Predictive Genomic Signatures Using Archival Paraffin-embedded Tumor Specimens in Breast Cancer N/A
Recruiting NCT04626986 - Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor N/A
Completed NCT04805775 - Desflurane and Postoperative Sleep Quality in Patients Undergoing Elective Breast Surgery N/A
Recruiting NCT03347864 - 68Ga-NOTA-RM26 PET/CT in Breast Tumor Patients Early Phase 1
Completed NCT03684408 - Radiofrequency Chip for Localization of Non-Palpable Breast Lesions N/A
Recruiting NCT04692818 - 3D Ultrasound Breast Imaging N/A
Not yet recruiting NCT04825444 - Clinical Study of Vascular Imaging Evaluation of Computed Tomography Photoacoustic Breast Imaging System
Recruiting NCT05252390 - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Withdrawn NCT02470819 - Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer N/A
Completed NCT00859261 - Two Dimensional (2D) Silicon Transducer-Compression Plates for Breast Ultrasound N/A
Active, not recruiting NCT05169437 - Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors Phase 2
Recruiting NCT03870620 - Metastatic Breast Cancer in Austria
Completed NCT05185752 - Comparative Analysis of Three Locoregional Anesthesia Methods in Breast Tumour Pathology Surgery N/A
Recruiting NCT04852926 - Study of the Sexual Health of Patients Treated for Breast Cancer and Followed up in the Observatory of Fertility at Jeanne de Flandre Hospital.
Recruiting NCT06172270 - Sub-regional Tumor Segmentation Based on CEUS Perfusion Characteristics: Enhancing Breast Tumor Diagnosis
Recruiting NCT04948983 - The Effect of a Patient Decision Aids for Breast Cancer Screening N/A
Not yet recruiting NCT06251544 - TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer Phase 1